IRF5
Interferon regulatory factor 5
Also known as: IRF-5, IRF5_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q13568
- Gene
- IRF5
- Ensembl
- ENSG00000128604
- Chromosome
- 7
- Canonical length
- 498 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins, Transcription factors
- Quaternary structure
- Homodimer
OverviewNCBI Gene
This gene encodes a member of the interferon regulatory factor (IRF) family, a group of transcription factors with diverse roles, including virus-mediated activation of interferon, and modulation of cell growth, differentiation, apoptosis, and immune system activity. Members of the IRF family are characterized by a conserved N-terminal DNA-binding domain containing tryptophan (W) repeats. Alternative promoter use and alternative splicing result in multiple transcript variants, and a 30-nt indel polymorphism (SNP rs60344245) can result in loss of a 10-aa segment. [provided by RefSeq, Dec 2016]
Canonical amino-acid sequenceUniProt
498 residues, UniProt reviewed canonical sequence.
>Q13568|IRF5
1 MNQSIPVAPT PPRRVRLKPW LVAQVNSCQY PGLQWVNGEK KLFCIPWRHA TRHGPSQDGD
61 NTIFKAWAKE TGKYTEGVDE ADPAKWKANL RCALNKSRDF RLIYDGPRDM PPQPYKIYEV
121 CSNGPAPTDS QPPEDYSFGA GEEEEEEEEL QRMLPSLSLT EDVKWPPTLQ PPTLRPPTLQ
181 PPTLQPPVVL GPPAPDPSPL APPPGNPAGF RELLSEVLEP GPLPASLPPA GEQLLPDLLI
241 SPHMLPLTDL EIKFQYRGRP PRALTISNPH GCRLFYSQLE ATQEQVELFG PISLEQVRFP
301 SPEDIPSDKQ RFYTNQLLDV LDRGLILQLQ GQDLYAIRLC QCKVFWSGPC ASAHDSCPNP
361 IQREVKTKLF SLEHFLNELI LFQKGQTNTP PPFEIFFCFG EEWPDRKPRE KKLITVQVVP
421 VAARLLLEMF SGELSWSADS IRLQISNPDL KDRMVEQFKE LHHIWQSQQR LQPVAQAPPG
481 AGLGVGQGPW PMHPAGMQLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IRF5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.44
- Highest tissue expression
- 16 nTPM
Expression across tissuesHPA
Tissue
- spleen: 16 nTPM
- bone marrow: 14 nTPM
- lymph node: 12 nTPM
- seminal vesicle: 11 nTPM
- appendix: 10 nTPM
- tonsil: 9.6 nTPM
Single-cell type
- microglia: 51 nCPM
- hofbauer cells: 48 nCPM
- monocyte progenitors: 40 nCPM
- monocytes: 39 nCPM
- macrophages: 32 nCPM
- kupffer cells: 31 nCPM
Immune cell
- intermediate monocyte: 51 nTPM
- myeloid DC: 42 nTPM
- classical monocyte: 40 nTPM
- non-classical monocyte: 37 nTPM
- total PBMC: 21 nTPM
- memory B-cell: 16 nTPM
Brain region
- white matter: 19 nTPM
- spinal cord: 13 nTPM
- hypothalamus: 13 nTPM
- medulla oblongata: 13 nTPM
- pons: 13 nTPM
- thalamus: 11 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about IRF5.
Disease | AllUniProt
Conditions IRF5 is implicated in, by any mechanism.
- Inflammatory bowel disease 14 (IBD14) MIM:612245
- Systemic lupus erythematosus 10 (SLEB10) MIM:612251
- Rheumatoid arthritis (RA) MIM:180300
Disease | ImmuneIEDB
Conditions an epitope on IRF5 was assayed in.
- multiple sclerosis B and T cell
- infectious mononucleosis B and T cell
- peripheral nervous system disease B cell
- neuromyelitis optica B cell
- rheumatoid arthritis B cell
- systemic lupus erythematosus B cell
- systemic scleroderma B cell
- Sjogren's syndrome B cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.6
- gnomAD pLI
- 0.01
- gnomAD missense Z
- 1.92
- DepMap mean gene effect
- 0
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- cellular response to muramyl dipeptide
- cellular response to peptidoglycan
- cellular response to virus
- cytokine-mediated signaling pathway
- defense response to virus
- immune system process
- inflammatory response
- innate immune response
- nucleotide-binding oligomerization domain containing 2 signaling pathway
- positive regulation of apoptotic process
- positive regulation of cytokine production involved in immune response
- positive regulation of interferon-alpha production
- positive regulation of interferon-beta production
- positive regulation of interleukin-12 production
- positive regulation of transcription by RNA polymerase II
- positive regulation of type I interferon production
- regulation of transcription by RNA polymerase II
Molecular functions
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA-binding transcription factor activity, RNA polymerase II-specific
- identical protein binding
- protein kinase binding
- protein serine/threonine kinase binding
- RNA polymerase II cis-regulatory region sequence-specific DNA binding
- sequence-specific DNA binding
- sequence-specific double-stranded DNA binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Interferon regulatory factor, DNA-binding domain
- SMAD/FHA domain superfamily
- SMAD-like domain superfamily
- Interferon regulatory factor-3
- Interferon regulatory factor, conserved site
- Winged helix-like DNA-binding domain superfamily
- Winged helix DNA-binding domain superfamily
- Interferon regulatory factor transcription factor
- Interferon-regulatory factor 3
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of IRF5 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IRF5 as an antibody target. Whether an autoantibody or antibody against IRF5 could matter depends on whether native IRF5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IRF5 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label IRF5 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...